Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Untapped Opportunity for Immune and Infl ammatory Biomarkers
- Diagnosing and Monitoring Immune and Infl ammatory Diseases
- Arthritic Conditions
- Rheumatoid Arthritis
- Juvenile Idiopathic Arthritis
- Ankylosing Spondylitis
- Systemic Lupus Erythematosus
- Pulmonary and Respiratory Conditions
- Asthma
- Chronic Obstructive Pulmonary Disease
- Infl ammatory Bowel Disease
- Crohn' s Disease
- Ulcerative Colitis
- Industry Trailblazers Advancing Biomarker Research and Product Development
- Musculoskeletal Immune/Infl ammatory Biomarker/Diagnostic Deals
- General Immune/Infl ammatory Biomarker/Diagnostic Deals
- Respiratory Immune/Infl ammatory Biomarker/Diagnostic Deals
- Strategic Considerations
- Major Breakthroughs Are Needed
- Consider the Value of Initiatives to Increase Awareness and Physician
Education
- Ability to Predict Response to Therapy Would Be a Game Changer
Tables
- 1. Immune and Infl ammatory Diseases Covered in This Report and Select
Associated Biomarkers
- 2. Lupus Foundation of America' s Top Ten Advances for Systemic Lupus
Erythematosus in 2008
- 3. Potential Biomarkers of Asthma and Chronic Obstructive Pulmonary Disease
- 4. Select Companies Focusing on Advancing Biomarker Opportunities in
Immune and Infl ammatory Diseases
Figures
- 1. Overall and Diagnosed Prevalence of Select Immune and Infl ammatory
Diseases in the United States, 2008
- 2. Pathological Changes in the Joints of Patients with Rheumatoid Arthritis
- 3. Rheumatologist-Estimated Percentage of Ankylosing Spondylitis Patients
with Common Ankylosing Spondylitis Symptoms
- 4. Comorbidities Associated with COPD
- 5. Percentage of Immune/Infl ammatory Biomarker/Diagnostic Deals by Deal
Focus
- 6. Percentage of Immune/Infl ammatory Biomarker/Diagnostic Deals by
Therapeutic Area
- 7. Percentage of Companies Involved in Immune/Infl ammatory
Biomarker/Diagnostic Deals by Company Type
|
Related Report
|
View Cart
